Abcam, ab258207, Human SRGN (Serglycin) knockout HeLa cell lysate

Size: 1Kit
SRGN KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 5 bp deletion in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 5 bp deletion in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SRGN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Serglycin also known as hematopoietic proteoglycan core protein is a critical component of the extracellular matrix with a mass of approximately 17 kDa. It plays an important mechanical role by serving as a scaffold for the attachment of glycosaminoglycan (GAG) chains. These chains help serglycin mediate the storage and secretion of various bioactive molecules. It is expressed predominantly in hematopoietic cells including mast cells neutrophils and macrophages and also in endothelial cells serving diverse biological functions through its ability to interact with a wide variety of molecules.
Biological function summary
Serglycin acts as a mediator of cell granule storage and release processes. It is essential in the storage of secretory granules in mast cells and is involved in the process of degranulation where it participates in inflammation response and hemostasis. Serglycin associates with various proteins forming complexes with them to facilitate the storage of inflammatory mediators such as histamine and proteases. Its ability to bind to and sequester these bioactive molecules plays significant roles in the regulation of both innate and adaptive immune responses.
Pathways
Serglycin is an integral part of the inflammatory response pathway and the coagulation cascade. In the inflammatory pathway it modulates the release and activity of key cytokines and chemokines thereby participating in the regulation of immune cell recruitment and activation. In the coagulation cascade it interacts with protease inhibitors and various clotting factors to regulate coagulation processes. Serglycin's relationships with proteins like cathepsin G and elastase further illustrate its involvement in these pathways enhancing the modulation of inflammatory and hemostatic responses.
Aberrations in Serglycin function or expression have been linked to several conditions including asthma and certain types of leukemia. In asthma it may influence the severity of the disease through its role in the storage and release of inflammatory mediators in mast cells. In leukemia especially acute myeloid leukemia alterations in Serglycin expression can affect leukemic cell survival and proliferation. These links between Serglycin and disease states often involve interaction with other proteins like chymase and platelet factor 4 which contribute to disease processes.